Bhawana Singh
Overview
Explore the profile of Bhawana Singh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
700
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Gedda M, Singh B, Kumar D, Singh A, Madhukar P, Upadhyay S, et al.
PLoS Negl Trop Dis
. 2020 Jul;
14(7):e0008221.
PMID: 32614818
Leishmaniasis remains a public health concern around the world that primarily affects poor folks of the developing world spanning across 98 countries with mortality of 0.2 million to 0.4 million...
12.
Varikuti S, Singh B, Volpedo G, Ahirwar D, Jha B, Saljoughian N, et al.
Br J Cancer
. 2020 Feb;
122(7):1005-1013.
PMID: 32025027
Background: Ibrutinib is a Bruton's tyrosine kinase (BTK) and interleukin-2-inducible kinase (ITK) inhibitor used for treating chronic lymphocytic leukaemia (CLL) and other cancers. Although ibrutinib is known to inhibit the...
13.
Singh B, Bhushan Chauhan S, Kumar R, Singh S, Ng S, Amante F, et al.
Parasite Immunol
. 2019 Sep;
41(11):e12669.
PMID: 31494954
CD8 T-cell function is compromised in chronic diseases such as visceral leishmaniasis (VL). However, little is known about the changes in gene expression that cause CD8+ T-cell dysfunction during VL....
14.
Fakiola M, Singh O, Syn G, Singh T, Singh B, Chakravarty J, et al.
PLoS Negl Trop Dis
. 2019 Aug;
13(8):e0007673.
PMID: 31419223
Amphotericin B provides improved therapy for visceral leishmaniasis (VL) caused by Leishmania donovani, with single dose liposomal-encapsulated Ambisome providing the best cure rates. The VL elimination program aims to reduce...
15.
Singh B, Varikuti S, Halsey G, Volpedo G, Hamza O, Satoskar A
Future Med Chem
. 2019 Aug;
11(15):1999-2018.
PMID: 31390889
Parasitic infections are responsible for significant morbidity and mortality throughout the world. Management strategies rely primarily on antiparasitic drugs that have side effects and risk of drug resistance. Therefore, novel...
16.
Varikuti S, Natarajan G, Volpedo G, Singh B, Hamza O, Messick G, et al.
Infect Immun
. 2019 Jun;
87(8).
PMID: 31182615
CD4 T helper 1 (Th1) cells producing interferon gamma (IFN-γ) are critical for the resolution of visceral leishmaniasis (VL). MicroRNA 155 (miR155) promotes CD4 Th1 responses and IFN-γ production by...
17.
Sundar S, Agrawal N, Singh B
Expert Opin Drug Metab Toxicol
. 2019 Jun;
15(7):595-612.
PMID: 31174439
: Being on the top list of neglected tropical diseases, leishmaniasis has been marked for elimination by 2020. In the light of small armamentarium of drugs and their associated drawbacks,...
18.
Schulte C, Barwari T, Joshi A, Theofilatos K, Zampetaki A, Barallobre-Barreiro J, et al.
Circ Res
. 2019 Jun;
125(3):328-340.
PMID: 31159652
Rationale: Noncoding RNAs (ncRNAs), including microRNAs (miRNAs), circular RNAs (circRNAs), and long noncoding RNAs (lncRNAs), are proposed novel biomarkers of myocardial injury. Their release kinetics have not been explored without...
19.
Chakravarty J, Hasker E, Kansal S, Singh O, Malaviya P, Singh A, et al.
PLoS Negl Trop Dis
. 2019 Mar;
13(3):e0007216.
PMID: 30917114
Background: Asymptomatic Leishmania donovani infections outnumber clinical presentations, however the predictors for development of active disease are not well known. We aimed to identify serological, immunological and genetic markers for...
20.
Bhushan Chauhan S, Faleiro R, Kumar R, Ng S, Singh B, Singh O, et al.
J Infect Dis
. 2019 Feb;
220(1):163-173.
PMID: 30796820
Control of visceral leishmaniasis (VL) caused by Leishmania donovani requires interferon-γ production by CD4+ T cells. In VL patients, antiparasitic CD4+ T-cell responses are ineffective for unknown reasons. In this...